Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer ...
SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its wholly-owned, CBL-B small molecule drug development program at …